Clinical Trials
Catherine Curtin, MD
Showing 1 - 5 of 5 trials – Showing only trials currently accepting patients
Study Title | Investigators | Stanford Study Status |
---|---|---|
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema |
Mark Nicolls Stanley G. Rockson, MD |
Recruiting |
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies |
Jennifer Caswell-Jin |
Recruiting |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
Melinda L. Telli, M.D. |
Recruiting |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
Irene Wapnir, MD |
Recruiting |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
Melinda L. Telli, M.D. |
Recruiting |
Dyani Gaudilliere, MD
Showing 1 - 5 of 5 trials – Showing only trials currently accepting patients
Study Title | Investigators | Stanford Study Status |
---|---|---|
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema |
Mark Nicolls Stanley G. Rockson, MD |
Recruiting |
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies |
Jennifer Caswell-Jin |
Recruiting |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
Melinda L. Telli, M.D. |
Recruiting |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
Irene Wapnir, MD |
Recruiting |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
Melinda L. Telli, M.D. |
Recruiting |
David Kahn, MD
Showing 1 - 5 of 5 trials – Showing only trials currently accepting patients
Study Title | Investigators | Stanford Study Status |
---|---|---|
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema |
Mark Nicolls Stanley G. Rockson, MD |
Recruiting |
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies |
Jennifer Caswell-Jin |
Recruiting |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
Melinda L. Telli, M.D. |
Recruiting |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
Irene Wapnir, MD |
Recruiting |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
Melinda L. Telli, M.D. |
Recruiting |
Gordon Lee, MD
Showing 1 - 5 of 5 trials – Showing only trials currently accepting patients
Study Title | Investigators | Stanford Study Status |
---|---|---|
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema |
Mark Nicolls Stanley G. Rockson, MD |
Recruiting |
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies |
Jennifer Caswell-Jin |
Recruiting |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
Melinda L. Telli, M.D. |
Recruiting |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
Irene Wapnir, MD |
Recruiting |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
Melinda L. Telli, M.D. |
Recruiting |
H. Peter Lorenz, MD
Showing 1 - 5 of 5 trials – Showing only trials currently accepting patients
Study Title | Investigators | Stanford Study Status |
---|---|---|
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema |
Mark Nicolls Stanley G. Rockson, MD |
Recruiting |
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies |
Jennifer Caswell-Jin |
Recruiting |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
Melinda L. Telli, M.D. |
Recruiting |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
Irene Wapnir, MD |
Recruiting |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
Melinda L. Telli, M.D. |
Recruiting |
Arash Momeni, MD
Showing 1 - 5 of 5 trials – Showing only trials currently accepting patients
Study Title | Investigators | Stanford Study Status |
---|---|---|
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema |
Mark Nicolls Stanley G. Rockson, MD |
Recruiting |
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies |
Jennifer Caswell-Jin |
Recruiting |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
Melinda L. Telli, M.D. |
Recruiting |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
Irene Wapnir, MD |
Recruiting |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
Melinda L. Telli, M.D. |
Recruiting |
Dung Nguyen, MD
Showing 1 - 5 of 5 trials – Showing only trials currently accepting patients
Study Title | Investigators | Stanford Study Status |
---|---|---|
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
Melinda L. Telli, M.D. |
Recruiting |
Trial of Acebilustat for the Treatment of Upper Arm Lymphedema |
Mark Nicolls Stanley G. Rockson, MD |
Recruiting |
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies |
Jennifer Caswell-Jin |
Recruiting |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
Irene Wapnir, MD |
Recruiting |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
Melinda L. Telli, M.D. |
Recruiting |